The randomized controlled trials (RCTs) summarized in Table 2 consistently demonstrate that GLP-1RAs, such as exenatide, semaglutide, and dulaglutide, significantly reduce albuminuria in patients with T2DM and CKD
Bose P, Pemmaraju N, Masarova L, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M , Cortes JE, Jain N, Borthakur G, Alvarado Y, Huynh-Le J, Henriquez M, Richie MA, Dobbins M, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S
e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [seeWarnings and Precautions (5.1)]
Was the vial left out
[19] Gejl, M., & Egefjord, L
Use of GLP-1 receptor agonists in pregnancy and reproductive safety: results from the European Teratology Information Services study